Page last updated: 2024-12-07

prunin protein, prunus

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

naringenin-7-O-glucoside: from Dracocephalum rupestre; has protective effects against doxorubicin-induced apoptosis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

prunin protein, Prunus: a legumin-like type of globulin; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

naringenin 7-O-beta-D-glucoside : A flavanone 7-O-beta-D-glucoside that is (S)-naringenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9910767
SCHEMBL ID2532187
MeSH IDM0118982
PubMed CID92794
CHEMBL ID469654
CHEBI ID28327
SCHEMBL ID318229
MeSH IDM0118982

Synonyms (53)

Synonym
MEGXP0_000353
ACON1_001258
529-55-5
naringenin-7-o-glucoside
NCGC00169525-01
BRD-A56567497-001-01-6
SCHEMBL2532187
DLIKSSGEMUFQOK-RGHIGTIISA-N
4',5,7-trihydroxyflavanone 7-o-.beta.-d-glucopyranoside
4h-1-benzopyran-4-one, 7-(.beta.-d-glucopyranosyloxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-, (2s)-
5-hydroxy-2-(4-hydroxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one
CHEBI:28327 ,
(s)-7-(beta-d-glucopyranosyloxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
(2s)-naringenin 7-o-beta-d-glucoside
(2s)-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2h-chromen-7-yl beta-d-glucopyranoside
C09099
naringenin 7-o-beta-d-glucoside
NCGC00163599-01
CHEMBL469654
unii-lsb8hdx4e5
lsb8hdx4e5 ,
einecs 208-464-8
prunin protein, prunus
pru du 6 protein, prunus
pru du 6.01 protein, prunus
pru2 protein, prunus
pru du 6.02 protein, prunus
pru1 protein, prunus
nsc 135064
CCG-208407
SCHEMBL318229
AC-35062
sr-05000013703
SR-05000013703-1
prunin, >=95% (lc/ms-elsd)
(s)-5-hydroxy-2-(4-hydroxyphenyl)-7-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)chroman-4-one
bdbm50249470
AKOS037515151
HY-N1549
(s)-5-hydroxy-2-(4-hydroxyphenyl)-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)chroman-4-one
Q15424791
DTXSID40967365
naringenin 7-0-glucoside
CS-0017098
naringenin 7-o-glucoside
(2s)-5-hydroxy-2-(4-hydroxyphenyl)-7-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy-2,3-dihydrochromen-4-one
naringenin 7-.beta.-d-glucoside, (-)-
naringenin 7-o-.beta.-d-glucoside
naringenin 7-o-.beta.-d-glucopyranoside
(2s)-7-(.beta.-d-glucopyranosyloxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
4h-1-benzopyran-4-one, 7-(.beta.-d-glucopyranosyloxy)-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-, (s)-
naringenin 7-glucoside
GLXC-14478

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The present data show that bioavailability of naringenin is increased by conversion from rutinoside to glucoside, but the profile of the conjugates of flavanones formed and excreted in urine is neither affected by the absorption site nor by a 3-fold change in dose."( Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects.
Barron, D; Bouisset, F; Bredsdorff, L; Cornett, C; Nielsen, IL; Offord, E; Rasmussen, SE; Williamson, G, 2010
)
0.36
" acidophilus LA85 may potentially contribute to the bioavailability of citrus flavanones, and to be applied as functional cultures to obtain more bioavailable and bioactive metabolites in food products or in the human gastrointestinal tract."( Biotransformation of two citrus flavanones by lactic acid bacteria in chemical defined medium.
Guo, A; Guo, X; Li, E, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
hypoglycemic agentA drug which lowers the blood glucose level.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
flavanone 7-O-beta-D-glucosideA beta-D-glucoside having a flavanon-7-yl moiety at the anomeric position.
dihydroxyflavanoneAny hydroxyflavanone carrying two hydroxy substituents.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
4'-hydroxyflavanonesAny hydroxyflavanone having a hydroxy substituent located at position 4'.
(2S)-flavan-4-oneAny flavanone in which the chiral centre at position 2 has S-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
naringenin glycoside biosynthesis08

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)3.76500.00000.503510.0000AID1073043; AID1073044
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)17.50000.00053.49849.7600AID1475098
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1073045Inhibition of Influenza A virus J/8178/09 neuraminidase by chemiluminescence based assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Computer-guided approach to access the anti-influenza activity of licorice constituents.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1073043Inhibition of oseltamivir-resistant Influenza A virus H1N1 B/55/08 neuraminidase by chemiluminescence based assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Computer-guided approach to access the anti-influenza activity of licorice constituents.
AID1475098Inhibition of PTP1B (unknown origin) using pNPP as substrate pretreated for 10 mins followed by substrate addition measured after 20 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Structure-related protein tyrosine phosphatase 1B inhibition by naringenin derivatives.
AID1766076Inhibition of preadipocyte differentiation in mouse 3T3-L1 cells assessed as lipid droplet accumulation at 100 uM incubated for 8 days by Oil Red O staining method relative to untreated control2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Phytochemicals from the flowers of Prunus persica (L.) Batsch: Anti-adipogenic effect of mandelamide on 3T3-L1 preadipocytes.
AID1073037Cytotoxicity against MDCK cells after 72 hrs2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Computer-guided approach to access the anti-influenza activity of licorice constituents.
AID1073039Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect at 50 uM after 48 hrs2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Computer-guided approach to access the anti-influenza activity of licorice constituents.
AID1766075Cytotoxicity against in mouse 3T3-L1 cells assessed as reduction in cell viability at 100 uM incubated for 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Phytochemicals from the flowers of Prunus persica (L.) Batsch: Anti-adipogenic effect of mandelamide on 3T3-L1 preadipocytes.
AID681587TP_TRANSPORTER: drug resistance (Mitoxantrone) in BCRP-expressing K562 cells2004Cancer research, Jun-15, Volume: 64, Issue:12
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
AID528043Antioxidant activity of the compound assessed as DPPH radical scavenging activity after 30 mins2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Flavonoids from Dracocephalum tanguticum and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells.
AID1475099Inhibition of alpha-glucosidase (unknown origin)2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Structure-related protein tyrosine phosphatase 1B inhibition by naringenin derivatives.
AID1475100Anti-diabetic activity in insulin-resistant human HepG2 cells assessed as increase in insulin-stimulated 2-NBDG uptake pretreated for 24 hrs followed by 2-NBDG addition measured after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Structure-related protein tyrosine phosphatase 1B inhibition by naringenin derivatives.
AID464265Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Flavanone and diphenylpropane glycosides and glycosidic acyl esters from Viscum articulatum.
AID1073042Inhibition of Influenza A virus (A/Hong Kong/1/1968(H3N2)) neuraminidase by chemiluminescence based assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Computer-guided approach to access the anti-influenza activity of licorice constituents.
AID336874Antihyperlipidemic effect in high fat diet-induced rat assessed as decrease in serum total cholesterol level at 10 mg/kg, ip relative to control
AID528046Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Flavonoids from Dracocephalum tanguticum and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells.
AID336872Antihyperlipidemic effect in high fat diet-induced rat assessed as decrease in serum triglyceride level at 10 mg/kg, ip relative to control
AID528045Antioxidant activity assessed as ABTS radical scavenging activity2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Flavonoids from Dracocephalum tanguticum and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells.
AID464263Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Flavanone and diphenylpropane glycosides and glycosidic acyl esters from Viscum articulatum.
AID1073044Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase by chemiluminescence based assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Computer-guided approach to access the anti-influenza activity of licorice constituents.
AID377040Hepatoprotective activity against H2O2-induced hepatotoxicity in Wistar rat hepatocytes assessed as reduction in glutamic pyruvate transaminase release after 1 hr relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Two new hepatoprotective stilbene glycosides from Acer mono leaves.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1475102Anti-diabetic activity in insulin-resistant human HepG2 cells assessed as increase in insulin-stimulated 2-NBDG uptake at 50 uM pretreated for 24 hrs followed by 2-NBDG addition measured after 30 mins by fluorescence assay relative to control2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Structure-related protein tyrosine phosphatase 1B inhibition by naringenin derivatives.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID336875Antihyperlipidemic effect in high fat diet-induced rat assessed as decrease in serum total cholesterol level at 20 mg/kg, ip relative to control
AID1073038Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect at 50 uM after 48 hrs2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Computer-guided approach to access the anti-influenza activity of licorice constituents.
AID681156TP_TRANSPORTER: drug resistance (SN-38) in BCRP-expressing K562 cells2004Cancer research, Jun-15, Volume: 64, Issue:12
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
AID336873Antihyperlipidemic effect in high fat diet-induced rat assessed as decrease in serum triglyceride level at 20 mg/kg, ip relative to control
AID528044Antioxidant activity assessed as ferrous ion chelating activity2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Flavonoids from Dracocephalum tanguticum and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells.
AID464264Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 1 to 20 uM after 24 hrs by MTT assay relative to control2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Flavanone and diphenylpropane glycosides and glycosidic acyl esters from Viscum articulatum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.57)18.7374
1990's2 (7.14)18.2507
2000's7 (25.00)29.6817
2010's15 (53.57)24.3611
2020's3 (10.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]